Bellon JR, Tayob N, Burstein HJ, Partridge A, et al. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer. Int J Radiat Oncol Biol Phys 2021;111.
PMID: 34700538